Mixed Schistosoma haematobium and S. mansoni infection: effect of different treatments on the serum level of circulating anodic antigen (CAA).
In this study, levels of circulating anodic antigen (CAA) in serum were investigated after differential treatment of 160 Sudanese patients with mixed Schistosoma haematobium and S. mansoni infections. The patients were randomly divided into four groups, which were treated with metrifonate (two doses of 10 mg/kg bodyweight), oxamniquine (60 mg/kg), praziquantel (40 mg/kg), or a multivitamin preparation, respectively. Serum, stool and urine samples were taken prior to treatment as well as one month and five months after chemotherapy. Before chemotherapy CAA levels were similar in the four groups. Antigenemia remained unchanged in the control group. In patients treated with praziquantel or oxamniquine the concentration of CAA decreased to a similar extent. However, whereas in the praziquantel group absence of CAA was already observed one month after treatment, clearing of CAA from the circulation seemed to take longer in patients treated with oxamniquine. Treatment with metrifonate did not result in a reduction of the CAA titres.
de Jonge
N
N
Laboratory of Parasitology, Medical Faculty, University of Leiden, The Netherlands.
Schommer
G
G
Feldmeier
H
H
Krijger
F W
FW
Dafalla
A A
AA
Bienzle
U
U
Deelder
A M
AM
D000818:Animals; D000947:Antigens, Helminth / Q000097:blood*; D002648:Child; D004797:Enzyme-Linked Immunosorbent Assay; D005243:Feces / Q000469:parasitology; D006801:Humans; D008297:Male; D010073:Oxamniquine / Q000627:therapeutic use; D010270:Parasite Egg Count; D011223:Praziquantel / Q000627:therapeutic use; D012548:Schistosoma haematobium / Q000276:immunology / Q000302:isolation & purification; D012550:Schistosoma mansoni / Q000276:immunology / Q000302:isolation & purification; D012553:Schistosomiasis haematobia / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D012555:Schistosomiasis mansoni / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D012556:Schistosomicides / Q000627:therapeutic use*; D014236:Trichlorfon / Q000627:therapeutic use; D014556:Urine / Q000469:parasitology
D000947:Antigens, Helminth; D012556:Schistosomicides; D010073:Oxamniquine; D011223:Praziquantel; D014236:Trichlorfon